Back to News
Market Impact: 0.45
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Source: Business Wire
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
MaaT Pharma said it is updating the potential development plan for MaaT013 (Xervyteg®) after the European Medicines Agency's CHMP issued a negative opinion following re-examination. The setback materially reduces near-term regulatory approval prospects for the cancer therapy and creates uncertainty around its future development pathway.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.60
Ticker Sentiment
MAAT-0.85
More News
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead
- AI-related debt binge may pressure European bond markets
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over